News

Mauna Kea Technologies confirms its eligibility to the French PEA-PME investment vehicles for 2017/2018

20 March 2017

Paris, March 20th 2017 – Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today confirmed it is eligible to the PEA-PME investment vehicles, according to decree n° 2014‐283 dated 4 March 2014, ruling on the PEA-PME eligibility criteria for companies.

Investors can continue to place their stocks of Mauna Kea Technologies with their PEA-PME accounts, which are investment vehicles dedicated to small and medium size public and private companies and which provide identical fiscal regime and incentives than the original PME.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico. For more information on Mauna Kea Technologies, visit www.maunakeatech.com

Disclaimer

This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities. Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Mauna Kea Technologies registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on June 13, 2016 under number R.16-054 and available on the Company's website (www.maunakeatech.com), and to the development of economic situation, financial markets, and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Mauna Kea Technologies that differ significantly from the results, financial conditions, performances or achievements expressed in such forwardlooking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for, Mauna Kea Technologies shares in any country.

United States: Zack Kubow / Lee Roth The Ruth Group 646-536-7020 / 7012 zkubow@theruthgroup.com lroth@theruthgroup.com

U.S. Media: Kirsten Thomas The Ruth Group 508-280-6592 kthomas@theruthgroup.com

France and Europe NewCap: Investor Relations Florent Alba +33 (0)1 44 71 94 94 maunakea@newcap.eu

Latest News

Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio 

Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio 

Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio® 

Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio® 

Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024

Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024